Pfizer's Q2 2024 Financial Overview

Pfizer Inc. has reported robust financial results for the second quarter of 2024, highlighting a 3% operational revenue growth year-over-year despite an anticipated decline in COVID-related revenues. The company has also raised its full-year 2024 revenue guidance to a range of $59.5 to $62.5 billion, alongside an increased adjusted diluted EPS guidance to a range of $2.45 to $2.65.

The second-quarter revenues totaled $13.3 billion, reflecting an increase of $277 million or 2% compared to the same period last year. This growth was primarily driven by contributions from several acquired products, key in-line brands, and recent commercial launches. Excluding revenues from Comirnaty and Paxlovid, Pfizer's operational revenue growth was an impressive 14%.

Strategic Focus and Operational Execution

Dr. Albert Bourla, Chairman and CEO of Pfizer, expressed satisfaction with the company’s performance, stating, “We are driving progress toward our 2024 strategic priorities through solid execution across the company. I am pleased with the strong performance of our product portfolio in the second quarter led by several of our acquired products, key in-line brands, and recent commercial launches. Notably, we achieved exceptional growth in our Oncology portfolio, with strong revenue contribution from our legacy-Seagen products.”

David Denton, Chief Financial Officer, emphasized the importance of the 14% operational revenue growth from non-COVID products in Q2 2024, marking Pfizer’s first quarter of topline revenue growth since Q4 2022. He highlighted the company’s continued focus on cost realignment and manufacturing optimization, which is expected to yield significant future margin expansions.

2024 Financial Guidance Update

Following the strong Q2 performance, Pfizer has adjusted its full-year 2024 financial guidance. The company now anticipates revenues in the range of $59.5 to $62.5 billion, an increase of $1 billion at the midpoint. The adjusted diluted EPS guidance has been raised by $0.30 at the midpoint, now expected to be between $2.45 and $2.65. Pfizer’s revenue projections include approximately $8.5 billion from Comirnaty and Paxlovid, with full-year operational revenue growth expected to be between 9% and 11%, excluding these COVID-related products.

Quarterly Financial Highlights

Pfizer's Q2 2024 revenues were driven by:

• Global revenues of $845 million from legacy Seagen, acquired in December 2023.
• Vyndaqel family products (Vyndaqel, Vyndamax, Vynmac) saw a 71% operational increase, mainly due to strong demand in the U.S. and international developed markets.
• Eliquis experienced an 8% operational growth, driven by market share gains in the non-valvular atrial fibrillation indication, especially in the U.S. and Europe.
• Nurtec ODT/Vydura revenues grew by 44% operationally, reflecting strong demand in the U.S. and new launches in international markets.

However, these gains were partially offset by declining revenues from:

• Xeljanz, which saw a 34% operational decline due to decreased prescription volumes and unfavorable changes in channel mix.
• Ibrance, down 8% operationally, mainly due to competitive pressure and price reductions in certain international markets.

Overall, Pfizer reported a Q2 2024 diluted EPS of $0.01 and an adjusted diluted EPS of $0.60, with the latter figure being affected by $1.3 billion in one-time costs associated with the company’s Manufacturing Optimization Program.

Highlights

• Pfizer raised its full-year 2024 revenue guidance to a range of $59.5 to $62.5 billion.
• Second-quarter 2024 revenues totaled $13.3 billion, up 2% year-over-year.
• Non-COVID product revenues grew 14% operationally in Q2 2024.
• Key product contributors included legacy Seagen, Vyndaqel, Eliquis, and Nurtec ODT/Vydura.
• Declines were noted in Xeljanz and Ibrance revenues.

Data Source: https://s28.q4cdn.com/781576035/files/doc_financials/2024/q2/Q2-2024-PFE-Earnings-Release.pdf